Published in Nat Commun on March 16, 2017
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 19.15
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol (2010) 5.65
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol (2006) 4.55
Toll-like receptors and cancer. Nat Rev Cancer (2008) 4.29
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science (2015) 4.23
Three-dimensional imaging of solvent-cleared organs using 3DISCO. Nat Protoc (2012) 3.19
A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood (2007) 3.09
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
TLR signaling by tumor and immune cells: a double-edged sword. Oncogene (2008) 2.18
Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest (2010) 2.02
Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res (2009) 1.85
Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia (2009) 1.66
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron (2009) 1.60
Toll-like receptor signaling pathways. Front Immunol (2014) 1.58
Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34+ cord blood cells. Hum Gene Ther (2003) 1.58
CpG still rocks! Update on an accidental drug. Nucleic Acid Ther (2012) 1.55
Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer (2010) 1.53
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest (2012) 1.45
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med (2010) 1.41
Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene (2013) 1.40
Complexity of danger: the diverse nature of damage-associated molecular patterns. J Biol Chem (2014) 1.32
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A (2012) 1.30
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30
The Yin and Yang of Toll-like receptors in cancer. Oncogene (2013) 1.23
Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther (2008) 1.23
Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother (2008) 1.23
Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res (2010) 1.21
Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol (2011) 1.10
Release and activity of histone in diseases. Cell Death Dis (2014) 1.10
Regulation of the anti-tumour immune response by cancer-associated fibroblasts. Semin Cancer Biol (2014) 1.07
RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells. Cell Death Differ (2014) 1.05
Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck (2009) 1.05
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology (2015) 1.02
Microbiome and Anticancer Immunosurveillance. Cell (2016) 0.97
Toll-like receptor 4 signaling promotes tumor growth. J Immunother (2010) 0.95
Pattern-recognition receptors and gastric cancer. Front Immunol (2014) 0.95
Toll-like receptors 3, 4 and 9 in hepatocellular carcinoma: Relationship with clinicopathological characteristics and prognosis. Hepatol Res (2013) 0.95
The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray. Electrophoresis (2009) 0.89
Innate sensing of microbial products promotes wound-induced skin cancer. Nat Commun (2015) 0.89
Optimization of an orthotopic murine model of head and neck squamous cell carcinoma in fully immunocompetent mice--role of toll-like-receptor 4 expressed on host cells. Cancer Lett (2011) 0.87
Toll-like receptor-4 expression by stromal fibroblasts is associated with poor prognosis in colorectal cancer. J Immunother (2013) 0.85
Induction of c-Myc-dependent cell proliferation through toll-like receptor 3 in head and neck cancer. Int J Mol Med (2008) 0.84
S100A9 induced inflammatory responses are mediated by distinct damage associated molecular patterns (DAMP) receptors in vitro and in vivo. PLoS One (2015) 0.80
Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes. PLoS One (2014) 0.80
More than a scaffold: Stromal modulation of tumor immunity. Biochim Biophys Acta (2015) 0.78
Distinct expression patterns of Toll-like receptor 7 in tumour cells and fibroblast-like cells in oral squamous cell carcinoma. Histopathology (2015) 0.77
TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. Cytokine (2016) 0.76
Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands. Cancer Immunol Immunother (2016) 0.76